AUG 12, 2015 11:28 AM PDT

Overstimulating Cancer Cells

Researchers at Baylor College of Medicine have developed a drug candidate that overstimulates proteins critical to tumor growth. In the August 10 issue of Cancer Cell, as reported in Science Daily, the researchers demonstrate that the drug candidate inhibits tumor growth in a mouse model of breast cancer and efficiently kills a broad range of human cancer cells. They claim that rapid cell division strains cancer cells, and "the approach works by tipping cell stress over the edge" (http://www.sciencedaily.com/releases/2015/08/150810132114.htm).
Cancer cells were treated with a control (left) and the overstimulating compound MCB-613 (right).
According to co-senior study author David Lonard of Baylor College of Medicine, "No prior drug has been previously developed or proposed that actually stimulates an oncogene to promote therapy. Our prototype drug works in multiple types of cancers and encourages us that this could be a more general addition to the cancer drug arsenal."

Cancer cells acquire mutations in oncogenes, which can transform cells into cancer cells. Research on identifying oncogenes that could be targeted by cancer drugs has uncovered the role of members of the steroid receptor coactivator (SRC) family of oncogenes. They appear to have great potential as therapeutic targets, because they are "at the nexus of key signaling pathways that cancer cells use to quickly grow, spread to other tissues, and acquire drug resistance," the researchers explain. In a prior investigation, Lonard and co-senior study author Bert O'Malley of Baylor College of Medicine screened compounds to discover "SRC-inhibiting molecules that kill a wide variety of cancer cells and inhibit tumor growth in animal models."

According to an article in the International Journal of Biological Sciences (Walsh CA, Qin L, Tien JCY, Young LS, Xu J. The Function of Steroid Receptor Coactivator-1 in Normal Tissues and Cancer. Int J Biol Sci 2012; 8(4):470-485. doi:10.7150/ijbs.4125), "Coregulator proteins were initially thought to be mere ‘acceptor proteins' that facilitated the interaction of specific ligand-bound nuclear receptors with general transcriptional machinery. Over the last seventeen years, however, complex and essential roles for a cohort of over 350 coactivator proteins have steadily emerged. Coregulator proteins have the uncanny ability to bind across unrelated families of transcription factors and coordinately facilitate the efficient and successful transcriptional activity of multiple target genes"
(http://www.ijbs.com/v08p0470.htm).

Lonard and O'Malley decided to disrupt key signaling pathways and kill cancer cells by overstimulating SRCs. They screened hundreds of thousands of compounds to identify a potent SRC activator, MCB-613, that killed human breast, prostate, lung, and liver cancer cells, while sparing normal cells. When they administered MCB-613 to 13 mice with breast cancer, the drug candidate almost completely eliminated tumor growth without causing toxicity, whereas tumors continued to grow in the control group of 14 mice.

O'Malley concludes, "We are optimistic that these drugs will eventually find their way into the clinic for use in patients."
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
OCT 19, 2019
Cancer
OCT 19, 2019
New Freezing Technique for Breast Cancer Patients in Low Income Countries
Treatment for breast cancer can be too expensive and hard to access for many women in lower-income countries. These women are disproportionately affected b...
OCT 19, 2019
Cancer
OCT 19, 2019
What zebra fish tell us about cancer tumors
New research published in PNAS from researchers at Duke University highlights a surprising finding: zebrafish have the ability to shed the lining of their ...
OCT 19, 2019
Cancer
OCT 19, 2019
Women with sleep apnea have higher rates of cancer
New research published in the European Respiratory Journal analyzed data on 20,000 adults with sleep apnea to conclude that women with severe sleep apnea h...
OCT 19, 2019
Cancer
OCT 19, 2019
Not the fried food!
Stop! Put down those fries! Although we know that fried foods aren’t good for our health (though they sure do taste good!), new research from UMass A...
OCT 19, 2019
Drug Discovery & Development
OCT 19, 2019
Insulin Drug Could Treat Glioblastoma
A molecule used for drug delivery of insulin was recently found by researchers at the University of Georgia’s Regenerative Bioscience Center to hold...
OCT 19, 2019
Drug Discovery & Development
OCT 19, 2019
How does a drug for colorectal cancer work?
Colorectal cancer is a fatal and common disease, and treatment decisions are often based on what genes have been mutated in the development of the cancer. ...
Loading Comments...